Sensyne Health PLC Directorate Change (5934R)
October 30 2019 - 2:41AM
UK Regulatory
TIDMSENS
RNS Number : 5934R
Sensyne Health PLC
30 October 2019
Directorate Change
Sensyne Health plc (LSE: SENS) ("Company"), the British clinical
AI technology company, announces that, further to the Board change
announcement made by the Company on 4 October 2019, Non-Executive
Chairman Charles Swingland has informed the Board of his intention
not to seek re-election at the Company's Annual General Meeting
("AGM") today due to continued ill health and he will step down as
a Director at the conclusion of the AGM.
As a consequence, Resolution 10 as set out in the AGM Notice has
been withdrawn.
Commenting on the announcement, Dr Annalisa Jenkins, Acting
Chairman, said:
"On behalf of the Board, I would like to wish Charles a full
recovery and thank him for his contribution to the Company."
-ENDS-
For more information please contact:
+44 (0) 330 058
Sensyne Health (www.sensynehealth.com) 1845
Dr Annalisa Jenkins, Acting Chairman
+ 44 (0) 20 7418
Peel Hunt LLP (Nominated Adviser and Broker) 8900
Dr Christopher Golden
James Steel
Oliver Jackson
+ 44 (0) 20 3100
Liberum (Joint Broker) 2000
Bidhi Bhoma
Euan Brown
Consilium Strategic Communications +44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a healthcare technology company that
creates value from accelerating the discovery and development of
new medicines and improving patient care through the analysis of
real-world evidence from large databases of anonymised patient data
in collaboration with NHS Trusts. These anonymised patient data are
ethically sourced in that any analysis of anonymised patient data
(and hence the Company's access to it) must be pre-approved for
each programme on a case-by-case basis by the relevant NHS Trusts.
This is to ensure that the purpose of the anonymisation and the
proposed analysis are subject to appropriate ethical oversight and
information governance, including conformance with NHS principles,
UK data protection law and applicable regulatory guidance. Sensyne
Health is an early signatory to the Department of Health and Social
Care's 'Initial Code of Conduct for data-driven health and care
technology.
Sensyne Health is listed on the AIM Market of the London Stock
Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAGRBDGRXXBGCG
(END) Dow Jones Newswires
October 30, 2019 03:41 ET (07:41 GMT)
Sensyne Health (LSE:SENS)
Historical Stock Chart
From Apr 2024 to May 2024
Sensyne Health (LSE:SENS)
Historical Stock Chart
From May 2023 to May 2024